{"id":53456,"date":"2023-01-31T14:02:25","date_gmt":"2023-01-31T13:02:25","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/"},"modified":"2023-01-31T14:02:25","modified_gmt":"2023-01-31T13:02:25","slug":"amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/","title":{"rendered":"Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023"},"content":{"rendered":"<div>\n<p>BRIDGEWATER, N.J.&#8211;(BUSINESS WIRE)&#8211;Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2023.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230131005199\/en\/803761\/5\/amneallogo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230131005199\/en\/803761\/21\/amneallogo.jpg\"><\/a><\/p>\n<p>\nThe financial results and live webcast will be accessible through the Investor Relations section of the Company&#8217;s website at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Finvestors.amneal.com&amp;esheet=53293615&amp;newsitemid=20230131005199&amp;lan=en-US&amp;anchor=https%3A%2F%2Finvestors.amneal.com&amp;index=1&amp;md5=3da6ce9efb3b089b1aac8b3dfa2a704f\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/investors.amneal.com<\/a>.\n<\/p>\n<p>\nTo access the call through a conference line, dial 1 (844) 200-6205 (in the U.S.) or 1 (929) 526-1599 (international callers). The access code for the call is 477511.\n<\/p>\n<p>\nA replay of the conference call will be posted shortly after the call and will be available for seven days. To access the replay, dial 1 (866) 813-9403 (in the U.S.) or +44 (204) 525-0658 (international callers). The access code for the replay is 942331.\n<\/p>\n<p>\n<b>About Amneal<\/b>\n<\/p>\n<p>\nAmneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals, primarily within the United States. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across a broad range of complex products and therapeutic areas, including injectables and biosimilars. In its Specialty segment, Amneal has a growing portfolio of branded pharmaceutical products focused primarily on central nervous system and endocrine disorders, with a pipeline focused on unmet needs. Through its AvKARE segment, the Company is a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. For more, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.amneal.com&amp;esheet=53293615&amp;newsitemid=20230131005199&amp;lan=en-US&amp;anchor=www.amneal.com&amp;index=2&amp;md5=c66f841e9c1529aa76d01a5d026c30a5\" rel=\"nofollow noopener\" shape=\"rect\">www.amneal.com<\/a>.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nAnthony DiMeo<br \/>\n<br \/>Head of Investor Relations<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;to&#x3a;&#x41;&#x6e;&#116;ho&#x6e;&#x79;&#x2e;&#68;&#105;M&#x65;&#x6f;&#x40;&#97;&#109;n&#x65;&#x61;&#x6c;&#46;&#99;om\" rel=\"nofollow noopener\" shape=\"rect\">&#x41;&#x6e;&#116;h&#x6f;&#x6e;&#121;&#46;D&#x69;&#x4d;&#101;o&#x40;&#x61;&#109;&#110;e&#x61;&#x6c;&#46;c&#x6f;&#x6d;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>BRIDGEWATER, N.J.&#8211;(BUSINESS WIRE)&#8211;Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2023. &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53456","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BRIDGEWATER, N.J.&#8211;(BUSINESS WIRE)&#8211;Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2023. ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-31T13:02:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230131005199\/en\/803761\/21\/amneallogo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023\",\"datePublished\":\"2023-01-31T13:02:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\\\/\"},\"wordCount\":294,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005199\\\/en\\\/803761\\\/21\\\/amneallogo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\\\/\",\"name\":\"Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005199\\\/en\\\/803761\\\/21\\\/amneallogo.jpg\",\"datePublished\":\"2023-01-31T13:02:25+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005199\\\/en\\\/803761\\\/21\\\/amneallogo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230131005199\\\/en\\\/803761\\\/21\\\/amneallogo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/","og_locale":"en_US","og_type":"article","og_title":"Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023 - Pharma Trend","og_description":"BRIDGEWATER, N.J.&#8211;(BUSINESS WIRE)&#8211;Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its fourth quarter and full year 2022 financial results on Thursday March 2, 2023, prior to market open. The Company will host a conference call and live webcast with the investment community at 8:30 a.m. Eastern Time on March 2, 2023. ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-31T13:02:25+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230131005199\/en\/803761\/21\/amneallogo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023","datePublished":"2023-01-31T13:02:25+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/"},"wordCount":294,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230131005199\/en\/803761\/21\/amneallogo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/","url":"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/","name":"Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230131005199\/en\/803761\/21\/amneallogo.jpg","datePublished":"2023-01-31T13:02:25+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230131005199\/en\/803761\/21\/amneallogo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230131005199\/en\/803761\/21\/amneallogo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/amneal-to-report-fourth-quarter-and-full-year-2022-results-on-march-2-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Amneal to Report Fourth Quarter and Full Year 2022 Results on March 2, 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53456","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53456"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53456\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53456"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53456"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}